Sol-Gel Analyst & Investor Day 2019 in NYC
Maxwell Hotel,
July 25, 2019
General Agenda
The event will include updates regarding our clinical development programs, commercial plans, and plans for advancing new pipeline candidates into clinical studies.
The event will feature presentations by management and leading dermatologists including:
- Linda Stein Gold, MD, Director of Dermatology Clinical Research at Henry Ford Health System
- Jeffrey Sugarman, MD, PhD, Medical Director Northern California Medical Associates, Assoc. Clinical Professor, University of California, San Francisco
- Mori Arkin, Chairman of The Board of Directors
- Alon Seri-Levy, PhD, Co-Founder and Chief Executive Officer
- John Vieira, U.S. Head of Commercialization
Click for Webcast

Sol-Gel Technologies Ltd.
[SLGL]
$119 MM MCap
Commercializing branded generic topical drug products (skin diseases). Two positive Phase 3 programs, both with PDUFA dates in 2021: Epsolay has potential to be first FDA-approved single-agent benzoyl peroxide prescription drug product for rosacea (PDUFA date on April 26th). Twyneo has potential to be the first acne treatment that contains fixed dose combination of BPO and tretinoin (PDUFA date on August 1st). [more information]
Event Contact

Joy Willis
Solebury Trout
Solebury Trout
Location of the Event and Other Places